Y Intercept Hong Kong Ltd acquired a new stake in shares of Grail, Inc. (NASDAQ:GRAL - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 28,016 shares of the company's stock, valued at approximately $500,000. Y Intercept Hong Kong Ltd owned 0.08% of Grail at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in GRAL. TCW Group Inc. bought a new position in shares of Grail in the fourth quarter worth approximately $5,095,000. abrdn plc bought a new stake in shares of Grail during the 4th quarter valued at $3,768,000. Douglas Lane & Associates LLC purchased a new position in shares of Grail during the 4th quarter valued at $3,034,000. Slow Capital Inc. bought a new position in Grail in the 4th quarter worth $2,379,000. Finally, 180 Wealth Advisors LLC purchased a new stake in Grail in the 4th quarter worth $1,681,000.
Grail Trading Down 7.8 %
Shares of GRAL stock traded down $3.23 during trading hours on Wednesday, hitting $38.30. The stock had a trading volume of 1,740,747 shares, compared to its average volume of 1,204,500. Grail, Inc. has a one year low of $12.33 and a one year high of $63.99. The stock's 50-day moving average price is $30.09 and its two-hundred day moving average price is $20.61.
Grail (NASDAQ:GRAL - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.41) by $2.55. The firm had revenue of $38.25 million during the quarter, compared to the consensus estimate of $35.33 million. Equities research analysts predict that Grail, Inc. will post -15.15 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities analysts have recently weighed in on GRAL shares. Morgan Stanley started coverage on Grail in a research note on Wednesday, November 27th. They issued an "equal weight" rating and a $16.00 price objective for the company. Wolfe Research assumed coverage on shares of Grail in a research report on Friday, November 15th. They set a "peer perform" rating for the company.
View Our Latest Analysis on GRAL
Grail Profile
(
Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Featured Stories
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
